409A Valuations Pre-IPO: What Changes as You Approach an Offering
Author: Redwood Valuation Content Team
Published: September 12, 2026
As an IPO becomes a realistic near-term outcome, the 409A process typically changes in three ways: the illiquid start-up safe harbor may become unavailable, valuations may be refreshed more often, and recent grants draw more scrutiny. For nonstatutory stock options and stock appreciation rights, the underlying valuation question does not change: whether the exercise price is at least the fair market value of the underlying common stock on the grant date. ASC 718 and pre-IPO disclosure review also become more important, but they involve different questions from the §409A valuation analysis.
What Actually Changes as an IPO Gets Real
For convenience, this article uses “stock-right exclusion” to refer to the §409A rules that keep a qualifying nonstatutory option or stock appreciation right outside §409A. One of the required conditions is valuation-related: the exercise price cannot be lower than the fair market value of the underlying common stock on the grant date. That grant-date benchmark does not change as an IPO approaches. What changes is which valuation method may receive a presumption of reasonableness and how closely the resulting values are reviewed.
| Changes | Does not change |
|---|---|
| The illiquid start-up presumption can become unavailable; many companies then obtain an independent valuation | For nonstatutory options and stock appreciation rights, fair market value of the underlying common stock remains the key stock-right measurement |
| Refresh cadence often tightens as a matter of practice | The grant date remains the measurement date for the stock-right fair market value test |
| Grant history and the valuations supporting it draw closer financial-reporting and disclosure scrutiny | §409A can still apply to some compensation arrangements beyond stock options |
That last row is easy to overlook: §409A is broader than a stock option rule. Restricted stock units and bonus arrangements can fall under §409A when payment is deferred beyond the short-term deferral rules in Treas. Reg. §1.409A-1(b)(4). Non-statutory stock options and stock appreciation rights can also fall within §409A when they do not satisfy the stock-right exclusion, including when the exercise price is below fair market value. So the compensation arrangements worth checking before you file extend beyond the option ledger, although the valuation question differs by award type.
Why the Illiquid Start-Up Safe Harbor Stops Working Pre-IPO
For convenience, this article uses three shorthand labels for the valuation presumptions. Method 1 is an independent appraisal, Method 2 is a qualifying formula valuation, and Method 3 is the illiquid start-up presumption. The corresponding provisions are Treas. Reg. §1.409A-1(b)(5)(iv)(B)(2)(i), (ii), and (iii). The three safe harbor methods are covered in detail elsewhere.
Method 3 is unavailable once a public offering is reasonably anticipated within 180 days of the grant or other action the valuation supports (Treas. Reg. §1.409A-1(b)(5)(iv)(B)(2)(iii)). The company does not choose to leave Method 3; the method becomes unavailable when its own qualifying conditions fail.
Method 3 applies only where each of these conditions holds:
The corporation has no material trade or business that it or any predecessor has conducted for 10 years or more
It has no class of equity securities traded on an established securities market
The stock is not subject to a put, call, or other right or obligation to purchase it, apart from a right of first refusal on a third-party offer or a lapse restriction
No change in control event is reasonably anticipated within 90 days of the action the valuation is applied to
No public offering of securities is reasonably anticipated within 180 days of the action the valuation is applied to
As an IPO approaches, Method 3's 180-day public-offering condition is the one most directly implicated. Because it is forward-looking, the question is when an offering becomes reasonably anticipated, not when a registration statement is filed. Method 3 also requires a written report prepared by someone the company reasonably determines is qualified, but it does not require an outside appraiser. So the pre-IPO issue is that Method 3 can become unavailable, not that it suddenly starts requiring an outside appraiser.
Once Method 3 becomes unavailable, many companies approaching an offering turn to Method 1 to obtain a valuation presumption. Method 2 can also remain available if its own conditions are met, so Method 1 is not the only possible presumption. Method 1 requires an independent appraisal that meets the requirements of §401(a)(28)(C) and the regulations, including the requirements for an independent appraiser. The appraisal must value the stock as of a date no more than 12 months before the relevant transaction. That 12-month limit constrains the valuation date; it does not guarantee that the valuation remains usable for a full year. Provider and cost tradeoffs are discussed in the breakdown of 409A valuation costs by stage.
The presumption is worth having: where it applies, the IRS can rebut the valuation only by showing that the method or its application was grossly unreasonable. Without the presumption, the valuation is evaluated under the general facts-and-circumstances reasonableness standard.
The tax consequences of a nonqualified option priced below fair market value fall mainly on the option holder. The employee can face ordinary income inclusion, a 20% additional income tax, and a premium interest tax. The company also has withholding and reporting obligations on amounts includible under §409A. Those consequences are one reason the valuation support behind pre-IPO grants matters.
How Often Pre-IPO Companies Refresh Their 409A
A tighter refresh cadence as an IPO approaches is not arbitrary, even though no regulation requires quarterly valuations. As the offering gets closer, recent grants receive more scrutiny, and intervening events can make an older valuation less reliable as support for current grant-date values. Companies therefore often move from annual valuations toward roughly quarterly updates while continuing to reassess sooner when material events occur. Interpolation or extrapolation between valuation dates can still be appropriate when supportable, but it becomes harder to rely on stale assumptions as the company's facts and the offering outlook change.
The 12-month figure appears in two separate rules, but neither makes a 409A valuation automatically valid for a year. Under Method 1, the independent appraisal must determine value as of a date no more than 12 months before the transaction it supports. Separately, the general reasonable-valuation rule at Treas. Reg. §1.409A-1(b)(5)(iv)(B)(1) treats a previously calculated value as unreasonable if it is more than 12 months old or no longer reflects material later information. Twelve months is therefore a ceiling, not a guaranteed shelf life.
One clarification: the roughly 90-day quarterly cadence is a practice convention, while Method 3's separate 90-day rule concerns a reasonably anticipated change in control. They share a number and nothing else.
Events that commonly prompt a refresh conversation include a new priced round, a significant secondary transaction in common stock, a material change in projections, or concrete offering steps such as engaging underwriters. None of these automatically requires a new valuation. What matters is whether the new information may materially affect value.
A secondary transaction can also provide important market evidence. How much weight it deserves depends on factors such as how recent it is, whether its pricing is consistent with other observed transactions, what information the parties had, whether the transaction was substantive to them, and whether the buyers reflect participants in the relevant market.
What Gets Reviewed When You File
As an IPO approaches, equity-compensation review increasingly focuses on whether the common-stock values assigned to recent grants remain supportable. Grants made close to the offering can draw particular scrutiny, especially when material events or changes in the company's outlook occur between valuation dates.
SEC staff guidance highlights several recurring considerations. Three are especially relevant here:
Timing and intervening events. How close the grants were to the offering, and what significant events occurred between valuation dates, can affect whether earlier common-stock values remain supportable.
The valuation process. The company's financial condition and prospects, the terms affecting the securities, and the objectivity of the valuation specialist all bear on the analysis.
Contemporaneous support. A valuation prepared at the time of the grant generally provides stronger evidence of the company's contemporaneous view than one reconstructed later.
As the offering approaches, the quality and documentation of the valuation process matter more.
How Your 409A Value and ASC 718 Values Relate
For a stock option, the §409A common-stock value and the ASC 718 award value answer different questions. They are related because the underlying common-share value used for §409A may also inform the current-price input used in an ASC 718 option valuation.
There are therefore three values to keep straight:
| Value | What it represents | Why it matters |
|---|---|---|
| §409A common-stock fair market value | Fair market value of the underlying common stock on the grant date | Helps determine whether a nonstatutory option or stock appreciation right satisfies the §409A stock-right exclusion |
| ASC 718 current-price input | The underlying common-share value used as an input to the award valuation | Feeds into the option's grant-date fair value |
| ASC 718 option fair value | The grant-date fair value of the option award itself | Used to measure compensation cost |
Eligible nonpublic entities may elect an ASC 718 practical expedient for the current-price input. Under that expedient, the input is determined through a reasonable application of a reasonable valuation method with characteristics similar to §409A. ASC 718 then measures the option itself separately, using that share-price input along with the exercise price, expected term, volatility, risk-free rate, dividends, and other applicable option-pricing inputs.
Keeping the underlying common-share value separate from the award-level fair value matters in a pre-IPO filing. "Cheap stock" review focuses on whether the fair value assigned to common stock underlying pre-IPO grants can be reconciled with the expected IPO price. Cheap stock is not a §409A safe harbor concept, and it is separate from the ASC 718 calculation of an option's total grant-date fair value. The §409A common-stock value and the ASC 718 underlying-share input may rely on closely related evidence even though the option award itself has a different fair value.
A second comparison involves the price of preferred stock. A lower common-stock value than the per-share price of the most recent preferred round is not, by itself, evidence of noncompliance. Preferred shares often carry liquidation preferences and other rights that common shares do not. The size of the gap still needs support from the capital structure, timing, market evidence, and valuation analysis. The preferred-round price can be important evidence for valuing common stock. It does not set a mandatory ceiling or dictate the common-stock value.
How much weight a recent preferred round receives depends on the facts. A backsolve or Option Pricing Method (OPM) analysis may use the round as important evidence, while income- or market-based indications may also matter when circumstances support them. Time elapsed and a materially changed outlook can affect the weight placed on the financing. The conclusion should follow from the evidence rather than from a fixed formula.
Two Workstreams, Not One
As an IPO approaches, two related but distinct workstreams become more important. One addresses stock rights and valuation presumptions under §409A; the other addresses ASC 718 accounting and pre-IPO disclosure. The rules differ, even though some of the same common-stock valuation evidence can inform both. The practical task is to keep the analyses separate while making sure the values used in each can be explained consistently.
Frequently Asked Questions
Can we keep using an internal 409A valuation once an IPO is on the table?
Not if you want to rely on the illiquid start-up presumption. Once a public offering is reasonably anticipated within 180 days of the grant or other action the valuation supports, that presumption is unavailable. An internally prepared valuation may still be evaluated under the general reasonableness rule, but it will not qualify for Method 1's independent-appraisal presumption.
Is our 409A valuation good for 12 months?
There is no general regulatory validity period that makes a 409A valuation automatically good for 12 months. Method 1 requires an appraisal with a valuation date no more than 12 months before the transaction it supports, and the general reasonableness rule also treats a value calculated more than 12 months earlier as unreasonable. Material new information can make an earlier value unreliable sooner. The relevant date is the valuation's effective date, not simply the day a report is issued.
Do we need a new 409A when we engage underwriters?
Possibly, but engaging underwriters is not an automatic regulatory refresh trigger. It is the kind of concrete offering development that can prompt a reassessment alongside a new priced round, a significant secondary transaction in common stock, or a material change in projections. The question is whether the new information may materially affect value.
Does §409A apply to anything besides stock options?
Yes. Some restricted stock units and bonus arrangements can fall under §409A when payment is deferred beyond the short-term deferral rules. Nonstatutory stock options and stock appreciation rights can also fall under §409A when they do not satisfy the stock-right exclusion, including when the exercise price is below fair market value. The applicable rule depends on the type of compensation arrangement. A pre-IPO review should therefore extend beyond the option ledger, but not every award raises the same valuation issue.
Does our board have to approve the 409A valuation?
No. Board approval is not a §409A requirement. A company may still make board approval or reliance on the valuation part of its governance process, but doing so is separate from qualifying for a valuation presumption. As an IPO approaches, the more important questions are whether the grant-date values remain supportable, whether material intervening events were addressed, and whether the valuation process was contemporaneous and objective.
Is "cheap stock" a §409A problem?
Not in the §409A safe-harbor sense. Cheap-stock review focuses on whether the value assigned to common stock underlying pre-IPO equity grants can be reconciled with the expected offering price. Some of the same evidence may support both that common-share value and the value used for §409A, but the analyses remain separate. The common-share value is also different from the ASC 718 fair value of the option award itself.